格隆汇2月27日丨普门科技(688389.SH)公布2025年度业绩快报，2025年度，公司实现营业总收入10.38亿 元，同比减少9.60%；实现归属于母公司所有者的净利润1.86亿元，同比减少46.12%；实现归属于母公 司所有者的扣除非经常性损益的净利润1.66亿元，同比减少49.28%。 2025年，受国内医保支付改革等行业政策影响，部分产品价格有所下调，公司国内业务收入与去年同期 相比有所下降；国际营销业务稳定增长，区域覆盖、本地化服务及市场准入工作持续推进。公司始终坚 持"聚焦主业"的发展战略，深耕体外诊断、临床医疗、皮肤医美、消费者健康市场，继续保持研发、营 销投入，不断丰富产品序列、深入拓展市场，努力提升公司的综合竞争力。 ...

新京报贝壳财经讯 2月27日，普门科技发布业绩快报，2025年度实现营业总收入10.38亿元，同比下降 9.60%；净利润1.86亿元，同比下降46.12%。2025年，受国内医保支付改革等行业政策影响，部分产品 价格有所下调，公司国内业务收入与去年同期相比有所下降；国际营销业务稳定增长，区域覆盖、本地 化服务及市场准入工作持续推进。 编辑 王进雨 ...

普门科技发布业绩快报，2025年度实现营业总收入10.38亿元，同比下降9.60%；净利润1.86亿元，同比 下降46.12%。2025年，受国内医保支付改革等行业政策影响，部分产品价格有所下调，公司国内业务 收入与去年同期相比有所下降；国际营销业务稳定增长，区域覆盖、本地化服务及市场准入工作持续推 进。 ...

证券日报网讯 2月5日，国际医学（000516）在互动平台回答投资者提问时表示，面对当前行业政策， 特别是医保支付改革的深化，公司与旗下医疗机构坚持规范运营，不断强化成本管控和效率提升，已在 优势专科建设、差异化业务布局上采取了一系列措施，实现了运营效率的持续优化、经营业绩的改善提 升。 ...

云南省政协第十三届委员会第四次会议和第十四届人民代表大会第四次会议在海埂会堂相继开幕。来自全省各条战线的人大代表和政协委员齐聚一堂，共 商发展大计，共绘云南高质量发展新蓝图。全国政协委员、一心堂药业集团董事长阮鸿献，省政协委员、一心堂药业集团副总裁阮国伟参会，积极履行委 员职责，围绕生物医药产业发展、中医药传承创新、医保支付改革、民生健康服务等关键领域提交多项提案，积极建言献策。 阮鸿献委员表示，真切感受"自己人"的温暖与信赖。近年来，云南省委、省政府持续优化营商环境，出台了一系列务实举措，真心实意支持民营经济发 展，深刻感受到了"把民营企业家当作自己人"的鲜明态度和温暖氛围，这让扎根云南、深耕发展的信心更加坚定。这种尊商、重商、亲商、安商的环境， 为民营企业大胆创新、放心投资提供了坚实后盾，也激励着广大企业家更积极地回馈社会、担当责任。将一如既往地聚焦国计民生、产业发展，充分发挥 委员作用，将企业的行业实践与政策建言紧密结合，为推动云南经济社会高质量跨越式发展贡献更多智慧和力量。 云南省第十四届人民代表大会第四次会议 取协云南省第十三届委员会第四次会议 HINDOCALLE (NE) e 代表大会强烈大会议 ...

□ 本报记者林惠虹余勤雍 最近，省内不同地区的网友通过"我请代表委员捎句话"留言，希望扩大慢性疾病筛查范围并加大筛查力 度。 省政协委员、东南大学附属中大医院内分泌科主任医师孙子林告诉记者，由他提交的关于基层慢病筛防 中心(以下简称CSP)相关提案，作为"健康江苏"建设的重要载体，已连续2年被纳入省政府民生实事项 目，作为"重要工程"持续推进，如今CSP已成为基层慢病防控体系中不可或缺的"哨点"与"枢纽"。 为进一步惠民利民，孙子林今年建议构建"激励相容"的医保-CSP协同发展新机制，以医保支付改革为杠 杆，引导资金从"末端治疗"向"前端预防和全程管理"倾斜，实现医保基金长期安全与居民健康水平提 升。 ...

Core Viewpoint - Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 54.93% to 66.20% compared to the previous year [2][4]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of between 18 million to 24 million yuan for 2025, a reduction of 29.25 million to 35.25 million yuan from the previous year [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between 11 million to 16 million yuan, reflecting a decrease of 33.29 million to 38.29 million yuan year-on-year [2][4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was 60.21 million yuan, with a net profit attributable to shareholders of 53.25 million yuan, and a net profit excluding non-recurring gains and losses of 49.29 million yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is attributed to multiple factors, including the deepening of pharmaceutical procurement policies, reforms in medical insurance payments, and intensified competition in the pharmaceutical market, leading to fluctuations in market demand from downstream customers, a decrease in product prices, and a reduction in sales volume [6].

Group 1 - The company Zhengchuan Co., Ltd. forecasts a net profit attributable to shareholders of 18 million to 24 million yuan for the year 2025, representing a decrease of 29.2488 million to 35.2488 million yuan compared to the previous year, which is a year-on-year decline of 54.93% to 66.2% [1] - The primary reasons for the performance change include the deepening of pharmaceutical procurement policies, healthcare payment reforms, and intensified competition in the pharmaceutical market, leading to fluctuations in market demand from downstream customers, a decline in product prices, and a reduction in product sales, which resulted in decreased operating revenue and a year-on-year decline in gross profit [1]

Core Viewpoint - Zhengchuan Co., Ltd. (603976.SH) expects a significant decline in net profit for the year 2025, primarily due to various market pressures and policy changes affecting the pharmaceutical industry [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 18 million to 24 million yuan for 2025, representing a decrease of 29.2488 million to 35.2488 million yuan compared to the previous year, which is a year-on-year decline of 54.93% to 66.20% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 11 million to 16 million yuan, reflecting a decrease of 33.2942 million to 38.2942 million yuan year-on-year, equating to a decline of 67.54% to 77.69% [1] Market Conditions - The anticipated decline in performance is attributed to the deepening of pharmaceutical procurement policies, reforms in medical insurance payments, and intensified competition in the pharmaceutical market [1] - Fluctuations in market demand from downstream customers, price reductions for certain products, and a decrease in product sales are contributing factors to the expected decline in operating revenue and gross profit [1]

Market Overview - The A-share market saw all three major indices rise, with the Shanghai Composite Index breaking the 4100-point mark for the first time in 10 years, closing at 4095.33, up 0.3% [1][2] - The Shenzhen Component Index increased by 0.57% to 14038.46, while the ChiNext Index rose by 0.1% to 3305.48 [2] - The total trading volume in the Shanghai and Shenzhen markets reached 2.08 trillion yuan, an increase of 296.3 billion yuan compared to the previous trading day [1][2] Sector Performance - Active sectors included energy metals, commercial aerospace, healthcare payment reform, AI applications, and computing hardware, while solar energy, semiconductors, and insurance sectors showed weakness [2] - The commercial aerospace sector experienced a surge, with multiple stocks hitting the daily limit, including Lushin Investment, which achieved 9 limit-ups in 11 days [2] AI and Technology Stocks - The AI application concept continued to strengthen, with stocks like Yuel Media and Easy Point Technology hitting the daily limit [3] - MiniMax, an AI model company, saw its stock price soar by 81% on its debut, later stabilizing at a 65% increase, with a market capitalization of 83.4 billion HKD [3] Precious Metals - Gold prices turned from gains to losses, with spot gold falling below 4470 USD, down nearly 0.3% [5][6] - Silver prices also declined, with spot silver dropping nearly 2% at one point, and futures contracts falling over 1% [5][6] Future Outlook - Guosen Securities predicts that with increased retail investor participation, the total incremental funds for the year could reach 2 trillion yuan [6] - The gold-silver ratio has dropped significantly, indicating potential profit-taking in the silver market, although there is speculation that silver prices may reach new highs around the Lunar New Year [6]